scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update on FUROSCIX ® , its investigational proprietary formulation of furosemide for subcutaneous administration. “As we look forward to our upcoming December 30, 2020 PDUFA date
October 8, 2020
· 6 min read